Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | NT5E | P21589 | 1/20 | 0.51 |
| ▸ | TACR2 | P21452 | 3/20 | 0.48 |
| ▸ | GJB2 | P29033 | 1/20 | 0.47 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.47 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.47 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.47 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.47 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 7/20 | 0.46 |
| ▸ | CDC25B | P30305 | 6/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1562064 | 1.00 | HTR1A (0.52) | HTR1ANT5ETACR2GJB2SSTR1 | |
| SCHEMBL19745164 | 1.00 | HTR1A (0.52) | HTR1ANT5ETACR2GJB2SSTR1 | |
| SCHEMBL13591465 | 1.00 | HTR1A (0.52) | HTR1ANT5ETACR2GJB2SSTR1 | |
| SCHEMBL14571365 | 1.00 | HTR1A (0.52) | HTR1ANT5ETACR2GJB2SSTR1 | |
| SCHEMBL17040197 | 1.00 | HTR1A (0.52) | HTR1ANT5ETACR2GJB2SSTR1 | |
| SCHEMBL1561736 | 1.00 | HTR1A (0.52) | HTR1ANT5ETACR2GJB2SSTR1 | |
| SCHEMBL20223437 | 1.00 | HTR1A (0.52) | HTR1ANT5ETACR2GJB2SSTR1 | |
| SCHEMBL13204990 | 1.00 | HTR1A (0.52) | HTR1ANT5ETACR2GJB2SSTR1 | |
| SCHEMBL2562480 | 1.00 | HTR1A (0.52) | HTR1ANT5ETACR2GJB2SSTR1 | |
| SCHEMBL12896357 | 1.00 | HTR1A (0.52) | HTR1ANT5ETACR2GJB2SSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278436-B2 | Glycosylated warfarin analogs and uses thereof | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-10-02 | — | — | US | claimed |
| US-20100267655-A1 | Glycosylated Warfarin Analogs and Uses Thereof | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-10-21 | — | — | US | claimed |
| WO-2010014814-A2 | GLYCOSYLATED WARFARIN ANALOGS AND USES THEREOF | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-02-04 | — | — | WO | claimed |
| US-6538131-B1 | By annulation of an olefinic intermediate; ring closing metathesis; a novel class of cyclopentene polyol intermediate products and anhydro derivatives thereof; fewer steps | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH | 2003-03-25 | — | — | US | claimed |
| JP-2002542252-A | — | — | 2002-12-10 | — | — | JP | claimed |
| EP-1178998-A4 | SYNTHETIC PROCESS FOR HIGHLY FUNCTIONALIZED CARBOCYCLIC POLYOLS AND SUBSTITUTED SUGAR ANALOGS | PICOWER INST MED RES (US) | 2002-11-13 | — | — | EP | claimed |
| EP-1178998-A1 | SYNTHETIC PROCESS FOR HIGHLY FUNCTIONALIZED CARBOCYCLIC POLYOLS AND SUBSTITUTED SUGAR ANALOGS | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 2002-02-13 | — | — | EP | claimed |
| WO-2000063220-A1 | SYNTHETIC PROCESS FOR HIGHLY FUNCTIONALIZED CARBOCYCLIC POLYOLS AND SUBSTITUTED SUGAR ANALOGS | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 2000-10-26 | — | — | WO | claimed |
| JP-2111783-A | — | — | None | — | — | JP | disclosed |
| EP-2170912-B3 | NEW PHOSPHORUS CONTAINING HETEROCYCLIC COMPOUNDS, SUGAR ANALOGUES, AND COMPOSITIONS HAVING ANTI-CANCER ACTIVITY CONTAINING THE SAME | CENTRE NAT RECH SCIENT (FR) | 2022-06-15 | — | — | EP | disclosed |
| CN-109843300-B | Crystalline polymorphic forms of a compound | 福斯特因公司 | 2021-08-27 | — | — | CN | disclosed |
| EP-3184112-B1 | SYNTHETIC INTERMEDIATE OF 1-(2-DEOXY-2-FLUORO-4-THIO-ß-D-ARABINOFURANOSYL)CYTOSINE | FUJIFILM CORP (JP) | 2020-12-23 | — | — | EP | disclosed |
| EP-3515454-B1 | CRYSTALLINE POLYMORPHIC FORM OF 3-HYDROXY-4,5-BIS-BENZYLOXY-6-BENZYLOXYMETHYL-2-PHENYL-2-OXO-2LAMBDA5-[1,2]OXAPHOSPHINANE | PHOSTIN (FR) | 2020-11-11 | — | — | EP | disclosed |
| CN-106349141-B | Polyhydroxy pyrrolidine compound and preparation method and application thereof | 中国科学院化学研究所 | 2020-10-27 | — | — | CN | disclosed |
| US-4943629-A | HYPOGLYCEMIC AGENTS; ENZYME STIMULATORS, INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1990-07-24 | — | — | US | disclosed |
| EP-0372157-A1 | Antidiabetic phosphonates | AMERICAN CYANAMID COMPANY (US) | 1990-06-13 | — | — | EP | disclosed |
| JP-H02111783-A | ANTIDIABETIC PHOSPHONATE | AMERICAN CYANAMID CO | 1990-04-24 | — | — | JP | disclosed |
| EP-0354323-A2 | Antidiabetic phosphates | AMERICAN CYANAMID COMPANY (US) | 1990-02-14 | — | — | EP | disclosed |
| EP-0354322-A2 | Antidiabetic alpha-substituted phosphonates | AMERICAN CYANAMID COMPANY (US) | 1990-02-14 | — | — | EP | disclosed |
| US-4745185-A | HYPOGLYCEMIC AGENTS | MCNEILAB, INC. (US) | 1988-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267655-A1 | Glycosylated Warfarin Analogs and Uses Thereof | GPI, UGGT1, GALE | HTR1A 4865/4885NT5E 422/4885TACR2 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.